127 related articles for article (PubMed ID: 11091130)
1. Transducer abstraction: a novel approach to the detection of partial agonist efficacy in radioligand binding studies.
Christopoulos A; Grant MK; El-Fakahany EE
J Pharmacol Toxicol Methods; 2000; 43(1):55-67. PubMed ID: 11091130
[TBL] [Abstract][Full Text] [Related]
2. Modulation of agonist binding by guanine nucleotides in CHO cells expressing muscarinic m1-m5 receptors.
van Giersbergen PL; Leppik R
Naunyn Schmiedebergs Arch Pharmacol; 1995 Aug; 352(2):166-72. PubMed ID: 7477439
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists.
Heldman E; Barg J; Fisher A; Levy R; Pittel Z; Zimlichman R; Kushnir M; Vogel Z
Eur J Pharmacol; 1996 Feb; 297(3):283-91. PubMed ID: 8666061
[TBL] [Abstract][Full Text] [Related]
4. Functional partial agonism at cloned human muscarinic acetylcholine receptors.
Bräuner-Osborne H; Ebert B; Brann MR; Falch E; Krogsgaard-Larsen P
Eur J Pharmacol; 1996 Oct; 313(1-2):145-50. PubMed ID: 8905341
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
6. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
7. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
[TBL] [Abstract][Full Text] [Related]
8. Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists.
Schwarz RD; Spencer CJ; Jaen JC; Mirzadegan T; Moreland D; Tecle H; Thomas AJ
Life Sci; 1995; 56(11-12):923-9. PubMed ID: 10188794
[TBL] [Abstract][Full Text] [Related]
9. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of McN-A-343 on membrane current and contraction in guinea pig ventricular myocytes.
Shen JB; Jiang B; Pappano AJ
J Pharmacol Exp Ther; 1999 Aug; 290(2):641-8. PubMed ID: 10411573
[TBL] [Abstract][Full Text] [Related]
11. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
Jakubík J; Bacáková L; El-Fakahany EE; Tucek S
Mol Pharmacol; 1997 Jul; 52(1):172-9. PubMed ID: 9224827
[TBL] [Abstract][Full Text] [Related]
12. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: the significance of Tyr403 in the binding of agonists and functional coupling.
Vogel WK; Sheehan DM; Schimerlik MI
Mol Pharmacol; 1997 Dec; 52(6):1087-94. PubMed ID: 9415719
[TBL] [Abstract][Full Text] [Related]
13. Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy.
Jakubík J; Janíčková H; El-Fakahany EE; Doležal V
Br J Pharmacol; 2011 Mar; 162(5):1029-44. PubMed ID: 20958290
[TBL] [Abstract][Full Text] [Related]
14. Interactions of agonists with M2 and M4 muscarinic receptor subtypes mediating cyclic AMP inhibition.
McKinney M; Miller JH; Gibson VA; Nickelson L; Aksoy S
Mol Pharmacol; 1991 Dec; 40(6):1014-22. PubMed ID: 1722002
[TBL] [Abstract][Full Text] [Related]
15. Effects of agonist efficacy on desensitization of phosphoinositide hydrolysis mediated by m1 and m3 muscarinic receptors expressed in Chinese hamster ovary cells.
Hu J; Wang SZ; el-Fakahany EE
J Pharmacol Exp Ther; 1991 Jun; 257(3):938-45. PubMed ID: 1710663
[TBL] [Abstract][Full Text] [Related]
16. Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist.
Zahn K; Eckstein N; Tränkle C; Sadée W; Mohr K
J Pharmacol Exp Ther; 2002 May; 301(2):720-8. PubMed ID: 11961078
[TBL] [Abstract][Full Text] [Related]
17. M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase.
Wotta DR; Wattenberg EV; Langason RB; el-Fakahany EE
Pharmacology; 1998 Apr; 56(4):175-86. PubMed ID: 9566019
[TBL] [Abstract][Full Text] [Related]
18. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
Ladner CJ; Lee JM
Exp Neurol; 1999 Aug; 158(2):451-8. PubMed ID: 10415152
[TBL] [Abstract][Full Text] [Related]
19. Receptor signaling mechanisms underlying muscarinic agonist-evoked contraction in guinea-pig ileal longitudinal smooth muscle.
Unno T; Kwon SC; Okamoto H; Irie Y; Kato Y; Matsuyama H; Komori S
Br J Pharmacol; 2003 May; 139(2):337-50. PubMed ID: 12770939
[TBL] [Abstract][Full Text] [Related]
20. Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists.
Wang SZ; el-Fakahany EE
J Pharmacol Exp Ther; 1993 Jul; 266(1):237-43. PubMed ID: 7687290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
